For DN, 22 potential urinary biomarkers and 12 disease-related signaling pathways were identified, and 21 combined medication regimens related to hypoglycemia, hypoglycemia and hypertension were proposed. For DM, 17 potential urinary biomarkers and 12 disease-related signaling pathways were identified, and 34 combined medication regimens related to hypoglycemia, hypoglycemia and hypertension, and hypoglycemia, hypertension and lipid-lowering were given. According to the enriched signaling pathways by the potential biomarkers and the therapy targets, the specific medication combinations were recommended for the specific clinical demands in terms of hypoglycemic, hypertensive and/or lipid-lowering. A NMR-based metabolomic strategy was applied to identify the potential urinary biomarkers of DM or/and DN, while network pharmacology was used to identify the therapy targets of DM and DN by intersecting the targets of diseases and currently approved drugs. In this study, the combination of metabolomics and network pharmacology was applied to provide the reasonable medication combination regimens to meet the different clinical needs for the targeted treatment of DM and DN. But the current approved drugs are usually tailored to clinical symptoms, no mechanisms-targeted drug is available. With the increasing prevalence of diabetes mellitus (DM) and diabetic nephropathy (DN), effective treatment is particularly important for the recovery of patients.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |